Significant association of cadaveric dura mater grafting with subpial Aβ deposition and meningeal amyloid angiopathy
- 759 Downloads
Recently, the possibility of human-to-human transmission of cerebral β-amyloidosis has been suggested in autopsy studies of patients with iatrogenic Creutzfeldt–Jakob disease (CJD) associated with human growth hormone injection or dura mater graft [1, 3, 4]. To evaluate the possibility of iatrogenic transmission of cerebral β-amyloidosis in humans via cadaveric dura mater graft, we performed immunohistochemical studies on 16 patients with dura mater graft-associated CJD (dCJD) and 21 patients with sporadic CJD (sCJD) using antibodies against prion protein (PrP), amyloid β-protein (Aβ), phosphorylated tau, phosphorylated α-synuclein, and phosphorylated transactive response DNA-binding protein-43 (TDP-43) (see supplementary methods). There were no significant differences between patients with dCJD and sCJD with respect to age at death [mean ± SD (range) years: 63.1 ± 14.1 (35–81) and 63.4 ± 10.8 (35–80), respectively], sex distribution, duration of CJD [months: 18.1 ± 8.8 (7–41) and...
KeywordsDura Mater Prion Protein Cerebral Amyloid Angiopathy Superficial Portion Deposition Score
This study was supported by a Grant-in-Aid from the Research Committee of Prion Disease and Slow Virus Infection; a Grant-in-Aid from the Research Committee of Surveillance and Infection Control of Prion Disease, the Ministry of Health, Labour and Welfare of Japan; a Grant-in-Aid from the Research Committee of Molecular Pathogenesis and Therapies for Prion Disease and Slow Virus Infection, Agency for Medical Research and Development (AMED); a Grant-in-Aid from the JSPS KAKENHI (26430060); a Grant-in-Aid from Scientific Research on Innovative Area (Comprehensive Brain Science Network) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.
- 5.Love S, Chalmers K, Ince P, Esiri M, Attems J, Jellinger K, Yamada M, McCarron M, Minett T, Matthews F et al (2014) Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J Neurodegener Dis 3:19–32PubMedPubMedCentralGoogle Scholar